OverviewChartNewsTraderScreen

Morgan Stanley Call 425 MDGL 20.1.../  DE000MG0D870  /

Stuttgart
6/7/2024  5:47:00 PM Chg.+0.020 Bid10:00:33 PM Ask10:00:33 PM Underlying Strike price Expiration date Option type
0.570EUR +3.64% -
Bid Size: -		 -
Ask Size: -		 Madrigal Pharmaceuti... 425.00 USD 12/20/2024 Call
GlobeNewswire 6/6 Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resme...
GlobeNewswire 6/5 Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conferenc...
GlobeNewswire 5/29 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes R...
GlobeNewswire 5/22 Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewswire 5/7 Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 4/24 Madrigal Statement on the Passing of Dr. Stephen Harrison
GlobeNewswire 4/23 Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, ...
GlobeNewswire 4/16 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 4/9 Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of...
GlobeNewswire 4/5 US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for ...
GlobeNewswire 4/4 GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 4/3 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 3/19 Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
GlobeNewswire 3/18 Madrigal Pharmaceuticals Announces Proposed Public Offering
GlobeNewswire 3/14 FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
GlobeNewswire 3/14 Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Pati...
GlobeNewswire 3/6 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 3/5 Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Res...
GlobeNewswire 2/28 Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
GlobeNewswire 2/28 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Fi...
GlobeNewswire 2/21 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 2/8 Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in th...
GlobeNewswire 2/6 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 1/29 Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
GlobeNewswire 1/22 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)